首页> 外文期刊>International Journal of Pharmaceutics >Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect.
【24h】

Development of docetaxel-loaded solid self-nanoemulsifying drug delivery system (SNEDDS) for enhanced chemotherapeutic effect.

机译:多西紫杉醇加载固体自纳乳化药物输送系统(SNEDDS)的开发,提高化学治疗效果。

获取原文
获取原文并翻译 | 示例
           

摘要

The main purpose of this study was to investigate the potential of self-nano-emulsifying drug delivery system (SNEDDS) in improving the bioavailability of docetaxel (DCT) and its chemotherapeutic effect. The DCT-loaded SNEDDS was prepared by employing rational blends of capryol 90, labrasol, and transcutol HP using ternary phase diagram. The liquid nano-emulsion was spray-dried into solid SNEDDS (D-SNEDDS) using an inert porous carrier, colloidal silica. The optimized formulation was characterized in terms of physico-chemical and pharmacokinetic parameters. Furthermore, anti-tumor efficacy of D-SNEDDS was compared with commercial marketed product, Taxotere(?). The various compositions of SNEDDS were screened and found optimal at a volume ratio of 10/75/15 for capryol 90, labrasol, and transcutol HP, respectively. We observed a high oral bioavailability of 17% DCT for D-SNEDDS than compared to only 2.6% for pure DCT solution. Notably, D-SNEDDS exhibited an augmented anti-tumor efficacy with a reduced toxicity profile when compared with intravenously administered Taxotere(?), the commercialized formulation of DCT. Taken together, D-SNEDDS could be a potential candidate for an oral dosage form of DCT with enhanced antitumor activity and reduced toxicity.
机译:本研究的主要目的是探讨自纳米乳化药物输送系统(SNEDDS)在提高多西紫杉醇(DCT)的生物利用度及其化学治疗效果的潜力。通过使用三元相图采用丙烯醇90,Labrasol和Transcutol HP的合理共混物来制备DCT负载的SnEdds。使用惰性多孔载体,胶体二氧化硅将液体纳米乳液喷雾成固体鼻涕(D-SnEdds)。优化的制剂的特征在于物理化学和药代动力学参数。此外,将D-Snedds的抗肿瘤疗效与商业销售产品,TAXOTERE(?)进行比较。筛选各种SnEdds的组合物,并分别以10/75/15用于烷醇90,Labrasol和Transcutol HP的体积比为最佳。我们观察到D-SNEDDS的高口气生物利用度为17%DCT,而不是纯DCT溶液的2.6%。值得注意的是,与静脉内施用的划屠杀(?),DCT商业化配方相比,D-Snedds表现出增强的抗肿瘤效果,毒性曲线减少。携带,D-SnEdds可以是具有增强抗肿瘤活性和降低毒性的DCT的口服剂型的潜在候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号